S. Birrell, R. Hall, and W. Tilley, Role of the androgen receptor in human breast cancer, Journal of Mammary Gland Biology and Neoplasia, vol.3, issue.1, pp.95-103, 1998.
DOI : 10.1023/A:1018730519839

S. Park, K. J. Park, H. Kim, J. Choi, S. Lee et al., Expression of androgen receptors in primary breast cancer, Annals of Oncology, vol.21, issue.3, pp.488-492, 2010.
DOI : 10.1093/annonc/mdp510

P. Farmer, H. Bonnefoi, V. Becette, M. Tubiana-hulin, P. Fumoleau et al., Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, vol.268, issue.29, pp.4660-4671, 2005.
DOI : 10.1023/A:1006356502820

A. Doane, M. Danso, P. Lal, M. Donaton, L. Zhang et al., An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen, Oncogene, vol.62, issue.28, pp.3994-4008, 2006.
DOI : 10.1038/sj.onc.1209415

M. Guedj, L. Marisa, A. De-reynies, B. Orsetti, R. Schiappa et al., A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2012.
DOI : 10.1038/nature09515

URL : https://hal.archives-ouvertes.fr/inserm-00611752

F. Moinfar, M. Okcu, O. Tsybrovskyy, P. Regitnig, S. Lax et al., Androgen receptors frequently are expressed in breast carcinomas, Cancer, vol.29, issue.4, pp.703-711, 2003.
DOI : 10.1002/cncr.11532

L. Marisa, A. De-reynies, and M. Guedj, citbcmst: Assigning tumor samples to CIT Breast Cancer Molecular Subtypes from gene expression data

A. Latil, I. Bièche, D. Vidaud, R. Lidereau, P. Berthon et al., Evaluation of androgen, estrogen (ER? and ER?), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays, Cancer Res, vol.61, pp.1919-1926, 2001.

J. Budczies, F. Klauschen, B. Sinn, B. Gy?rffy, W. Schmitt et al., Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization, PLoS ONE, vol.28, issue.8, p.51862, 2012.
DOI : 10.1371/journal.pone.0051862.s001

J. Lehmann-che, F. Amira-bouhidel, E. Turpin, M. Antoine, H. Soliman et al., Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches, British Journal of Cancer, vol.131, issue.11, pp.1739-1746, 2011.
DOI : 10.1159/000055396

J. Flaman, T. Frebourg, V. Moreau, F. Charbonnier, C. Martin et al., A simple p53 functional assay for screening cell lines, blood, and tumors., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3963-3967, 1995.
DOI : 10.1073/pnas.92.9.3963

F. Waridel, A. Estreicher, L. Bron, J. Flaman, C. Fontolliet et al., Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract, Oncogene, vol.14, issue.2, pp.163-169, 1997.
DOI : 10.1038/sj.onc.1200812

M. Varna, J. Lehmann-che, E. Turpin, E. Marangoni, E. Bouchtaoui et al., p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors, International Journal of Cancer, vol.104, issue.4, pp.53991-997, 2009.
DOI : 10.1002/ijc.24049

URL : https://hal.archives-ouvertes.fr/inserm-00498765

M. Santarpia, G. Altavilla, M. Margeli, B. Cirauqui, M. Mesiti et al., PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance, Cancer Investigation, vol.13, issue.24, pp.1044-1051, 2008.
DOI : 10.4161/cbt.3.12.1388

A. Wolff, M. Hammond, J. Schwartz, K. Hagerty, D. Allred et al., College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, College of American Pathologists Arch Pathol Lab Med, vol.131, pp.18-43, 2007.

A. Gown, Current issues in ER and HER2 testing by IHC in breast cancer, Modern Pathology, vol.5, issue.2, pp.8-15, 2008.
DOI : 10.1309/FUQH-92B0-3902-5LHG

L. Breiman, J. Friedman, R. Olshen, and C. Stone, Classification and Regression Trees London: Chapman and Hall, 1984.

Y. Shih, Selecting the best splits for classification trees with categorical variables, Statistics & Probability Letters, vol.54, issue.4, pp.341-345, 2001.
DOI : 10.1016/S0167-7152(00)00188-7

R. Development and C. Team, R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing, 2009.

B. Ripley, Tree: Classifcation and Regression Trees 2010. R package version 1.0- 28

O. Malley, F. Page, D. Nelson, E. Dupont, and W. , Ductal carcinoma in situ of the breast with apocrine cytology: Definition of a borderline category, Human Pathology, vol.25, issue.2, pp.164-168, 1994.
DOI : 10.1016/0046-8177(94)90273-9

F. Tavassoli and H. Norris, Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases, Mod Pathol, vol.7, pp.813-818, 1994.

F. Tavassoli and P. Devilee, World Health Organization: Tumours of the Breast and Female Genital Organs -Pathology and, 2003.

P. Zagorianakou, N. Zagorianakou, D. Stefanou, G. Makrydimas, and N. Agnantis, The enigmatic nature of apocrine breast lesions, Virchows Archiv, vol.193, issue.2, pp.525-531, 2006.
DOI : 10.1007/s00428-005-0095-z

B. Weigelt, H. Horlings, B. Kreike, M. Hayes, M. Hauptmann et al., Refinement of breast cancer classification by molecular characterization of histological special types, The Journal of Pathology, vol.9, issue.2, pp.141-150, 2008.
DOI : 10.1002/path.2407

J. Celis, T. Cabezón, J. Moreira, P. Gromov, I. Gromova et al., Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort, Molecular Oncology, vol.14, issue.1, pp.220-237, 2009.
DOI : 10.1016/j.molonc.2009.01.005

S. Vranic, Z. Gatalica, H. Deng, S. Frkovic-grazio, L. Lee et al., ER-??36, a novel isoform of ER-??66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast, Journal of Clinical Pathology, vol.64, issue.1, pp.54-57, 2011.
DOI : 10.1136/jcp.2010.082776

L. Niemeier, D. Dabbs, S. Beriwal, J. Striebel, and R. Bhargava, Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation, Modern Pathology, vol.10, issue.2, pp.205-212, 2010.
DOI : 10.1016/S0002-9610(03)00054-0

A. Albergaria, J. Paredes, B. Sousa, F. Milanezi, V. Carneiro et al., Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours, Breast Cancer Research, vol.20, issue.3, p.40, 2009.
DOI : 10.1016/j.ceb.2008.02.003

S. Baniwal, G. Little, N. Chimge, and B. Frenkel, Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation, Journal of Cellular Physiology, vol.104, issue.5, pp.2276-2282, 2012.
DOI : 10.1002/jcp.22966

M. Wick, T. Lillemoe, G. Copland, P. Swanson, J. Manivel et al., Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin, Human Pathology, vol.20, issue.3, pp.281-287, 1989.
DOI : 10.1016/0046-8177(89)90137-8

A. Gonzalez-angulo, K. Stemke-hale, S. Palla, M. Carey, R. Agarwal et al., Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer, Clinical Cancer Research, vol.15, issue.7, pp.2472-2478, 2009.
DOI : 10.1158/1078-0432.CCR-08-1763

F. Alimirah, R. Panchanathan, J. Chen, X. Zhang, S. Ho et al., Expression of Androgen Receptor Is Negatively Regulated By p53, Neoplasia, vol.9, issue.12, pp.1152-1159, 2007.
DOI : 10.1593/neo.07769

L. Collins, K. Cole, J. Marotti, R. Hu, S. Schnitt et al., Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study, Modern Pathology, vol.10, issue.7, pp.924-931, 2011.
DOI : 10.1093/jnci/djp082

S. Loibl, B. Müller, G. Von-minckwitz, M. Schwabe, M. Roller et al., Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.28, issue.6, pp.477-487, 2011.
DOI : 10.1007/s10549-011-1715-8

L. Gonzalez, M. Corte, J. Vazquez, S. Junquera, R. Sanchez et al., Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors, BMC Cancer, vol.25, issue.1, p.149, 2008.
DOI : 10.1677/jme.0.0250085

R. Hu, S. Dawood, M. Holmes, L. Collins, S. Schnitt et al., Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women, Clinical Cancer Research, vol.17, issue.7, pp.1867-1874, 2011.
DOI : 10.1158/1078-0432.CCR-10-2021

S. Agoff, P. Swanson, H. Linden, S. Hawes, and T. Lawton, Androgen Receptor Expression in Estrogen Receptor???Negative Breast Cancer, American Journal of Clinical Pathology, vol.120, issue.5, pp.725-731, 2003.
DOI : 10.1309/42F00D0DJD0J5EDT

X. Luo, Y. Shi, Z. Li, and W. Jiang, Expression and clinical significance of androgen receptor in triple negative breast cancer, Chinese Journal of Cancer, vol.29, issue.6, pp.585-590, 2010.
DOI : 10.5732/cjc.009.10673

G. Banneau, M. Guedj, G. Macgrogan, I. De-mascarel, V. Velasco et al., Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations, Breast Cancer Research, vol.15, issue.4, p.63, 2010.
DOI : 10.1038/nm.2000

URL : https://hal.archives-ouvertes.fr/hal-00698403

B. Lehmann, J. Bauer, X. Chen, M. Sanders, A. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Journal of Clinical Investigation, vol.121, issue.7, pp.2750-2767, 2011.
DOI : 10.1172/JCI45014DS1